| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
- Nomegestrol Acetate acts as a selective agonist of the progesterone receptor (PR). In rat uterine cytosolic PR binding assays, it exhibited a Ki value of 22.8 nM for PR, which is slightly higher than progesterone (34.3 nM)[1]
- Nomegestrol Acetate demonstrated high selectivity for PR with an EC50 of 0.3 nM in human PR-transfected Chinese Hamster Ovary (CHO) cells. It showed negligible activity on estrogen receptors (ERα/β, EC50 > 1000 nM), androgen receptors (AR, EC50 > 1000 nM), glucocorticoid receptors (GR, EC50 > 1000 nM), and mineralocorticoid receptors (MR, EC50 > 1000 nM)[2] |
|---|---|
| ln Vitro |
- Receptor Binding Selectivity: In radioligand binding assays using rat uterine cytosolic PR, Nomegestrol Acetate displayed a Ki of 22.8 nM for PR, confirming its high affinity. No significant binding to ER, AR, GR, or MR was detected under identical conditions[1]
- PR Transactivation: In CHO cells transfected with human PR and a luciferase reporter plasmid, Nomegestrol Acetate dose-dependently activated PR-mediated luciferase activity (EC50 = 0.3 nM). At concentrations up to 1000 nM, it did not activate ERα/β, AR, GR, or MR, confirming PR selectivity[2] Nomegestrol, a progestin, has a high affinity for the progesterone receptor, as evidenced by its Kd of 5.44 nM for the progesterone receptor in the rat uterus [1]. Although it has little to no binding affinity for other steroid receptors including androgen and glucocorticoid receptors, nomegestrol acetate, or NOMAC, is a highly selective complete agonist of the progesterone receptor. Strong antiestrogenic and moderate antiandrogenic properties can be seen in normegestrol acetate [2]. |
| ln Vivo |
- Ovulation Inhibition in Rats: Female Sprague-Dawley rats orally administered Nomegestrol Acetate at 0.01–0.1 mg/kg/day for 14 days showed dose-dependent ovulation inhibition: 25% inhibition at 0.01 mg/kg, 75% at 0.05 mg/kg, and 100% at 0.1 mg/kg. Vaginal smears confirmed suppression of estrous cyclicity[2]
- Ovulation Inhibition in Monkeys: Cynomolgus monkeys treated with Nomegestrol Acetate (0.5 mg/kg/day orally for 3 menstrual cycles) showed complete ovulation inhibition (serum progesterone < 2 ng/mL throughout treatment) without altering menstrual cycle length[2] |
| Enzyme Assay |
- PR Binding Assay (Rat Uterus Cytosol):
1. Rat uterine cytosolic fractions were prepared by homogenization and centrifugation.
2. Increasing concentrations of [³H]nomegestrol acetate (0.1–10 nM) were incubated with cytosolic PR at 4°C for 18 hours.
3. Bound and free ligands were separated by dextran-coated charcoal adsorption.
4. Specific binding was calculated by subtracting nonspecific binding (determined in the presence of 100-fold excess unlabeled progesterone).
5. Scatchard analysis yielded a Ki of 22.8 nM for Nomegestrol Acetate[1]
- PR Transactivation Assay (CHO Cells): 1. CHO cells were co-transfected with human PR expression plasmid, PRE-luciferase reporter, and β-galactosidase plasmid. 2. After transfection, cells were treated with Nomegestrol Acetate (0.01–100 nM) in serum-free medium for 24 hours. 3. Luciferase activity was normalized to β-galactosidase activity, and dose-response curves were fitted to determine EC50[2] |
| Animal Protocol |
- Rat Ovulation Inhibition Model:
- Subjects: Female Sprague-Dawley rats (200–220 g).
- Treatment: Nomegestrol Acetate dissolved in corn oil (0.01–0.1 mg/kg/day, oral gavage) for 14 days.
- Assessment: Daily vaginal smears to monitor estrous cycle; ovarian corpora lutea count on day 15[2]
- Monkey Ovulation Inhibition Model: - Subjects: Female cynomolgus monkeys (3–4 kg). - Treatment: Nomegestrol Acetate dissolved in peanut oil (0.5 mg/kg/day, oral gavage) for 3 menstrual cycles. - Assessment: Serum progesterone levels (ELISA) and menstrual cycle length monitoring[2] |
| ADME/Pharmacokinetics |
Human pharmacokinetics: - Absorption: After oral administration of 2.5 mg nomenoprogesterone acetate, the peak plasma concentration (Cmax = 3.2 ± 0.6 ng/mL) was reached at Tmax = 2.5 ± 0.5 hours. - Elimination: Terminal half-life (t1/2) = 30 ± 4 hours; oral bioavailability = 65 ± 8%. - Metabolism: Mainly metabolized by CYP3A4 to inactive metabolites. - Excretion: 70% is excreted in feces, 15% in urine, and excreted within 72 hours [2]
|
| Toxicity/Toxicokinetics |
Acute toxicity: No significant toxicity or death was observed in rats and monkeys at doses up to 0.1 mg/kg (rat) and 0.5 mg/kg (monkey).[2] - Subchronic toxicity: In a 14-day rat study, nomenoprogesterone acetate did not affect body weight, food intake, or serum biochemical parameters (ALT, AST, BUN).[2] - Plasma protein binding: Nomenoprogesterone acetate was 99% bound to plasma proteins, primarily albumin.[2]
|
| References | |
| Additional Infomation |
Mechanism of action: Nomeprogesterone acetate exerts its contraceptive effect by regulating the hypothalamic-pituitary axis to inhibit the luteinizing hormone (LH) surge and ovulation [2]
- Clinical application: Approved in Europe as a component of combined oral contraceptives (e.g., Zoyri®) for use in combination with 17β-estradiol [2] - Metabolic profile: Has no effect on lipid and glucose metabolism, and no significant effect on blood pressure or coagulation parameters in preclinical models [2] Nomeprogesterone is a corticosteroid hormone. Nomeprogesterone is a component of Zoyri®, an EMA-approved product. |
| Molecular Formula |
C21H28O3
|
|---|---|
| Molecular Weight |
328.44
|
| Exact Mass |
328.203
|
| Elemental Analysis |
C, 76.79; H, 8.59; O, 14.61
|
| CAS # |
58691-88-6
|
| Related CAS # |
Nomegestrol acetate;58652-20-3
|
| PubChem CID |
68783
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
502.6±50.0 °C at 760 mmHg
|
| Melting Point |
204-205ºC
|
| Flash Point |
271.8±26.6 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
2.58
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
24
|
| Complexity |
673
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC([C@@]1(O)CC[C@@]2([H])[C@]3([H])C=C(C)C4=CC(CC[C@]4([H])[C@@]3([H])CC[C@]12C)=O)=O
|
| InChi Key |
KZUIYQJTUIACIG-YBZCJVABSA-N
|
| InChi Code |
InChI=1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1
|
| Chemical Name |
(8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
|
| Synonyms |
Nomegestrol; 58691-88-6; Nomegestrolum; 19-Norpregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-; 10F89177CO; 17-Hydroxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione; RefChem:854426; G03DB04;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0447 mL | 15.2235 mL | 30.4470 mL | |
| 5 mM | 0.6089 mL | 3.0447 mL | 6.0894 mL | |
| 10 mM | 0.3045 mL | 1.5223 mL | 3.0447 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
